Mesoblast (ASX:MSB) entered an agreement with the US Centers for Medicare & Medicaid Services, enabling access to its US Food and Drug Administration-approved therapy, Ryoncil, according to a Monday filing with the Australian bourse.
The agreement ensures coverage for about 40% of US children with steroid-refractory acute graft versus host disease, with mandatory coverage starting July 1, the filing said.
The therapy is available to both Medicaid and privately insured children, and the first treatments are set to start this week, the filing added.
Shares of the firm fell almost 1% in recent Monday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。